Argus Research Reaffirms Buy Rating for DexCom, Adjusts Price Target to $90
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 84.81 USD with a low forecast of 68.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
19 Buy
3 Hold
1 Sell
Strong Buy
Current: 73.670
Low
68.00
Averages
84.81
High
112.00
Current: 73.670
Low
68.00
Averages
84.81
High
112.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Previous Stock Selections Subtly Indicate Buy Opportunities Once More
- Market Opportunities: Investors may find renewed opportunities in previously recommended stocks from healthcare, oil services, and consumer staples sectors.
- Signs of Momentum: These stocks are showing signs of renewed momentum, suggesting potential upside for investors.
- Sector Rotation: The leadership in these sectors has already rotated, indicating a shift in market dynamics.
- Investor Consideration: Investors are encouraged to take a fresh look at these stocks as they may present attractive investment options.
Continue Reading
Kaskela Law Investigates Potential Fiduciary Breach at DexCom
- Investigation Launched: Kaskela Law LLC is investigating potential breach of fiduciary duty claims against DexCom, Inc. (NASDAQ:DXCM) to protect the interests of long-term investors and ensure transparency and compliance in corporate governance.
- Securities Fraud Complaint: A securities fraud complaint filed against DexCom alleges that during the period from April 28, 2023, to July 25, 2024, senior executives made a series of materially false statements, potentially causing significant investor losses.
- Earnings Guidance Cut Impact: On July 25, 2024, DexCom shocked the market by slashing its full-year revenue guidance by $300 million, primarily due to severe underperformance in the Type 2 basal market, leading to a more than 40% drop in stock price to $64.00 per share the following day.
- Shareholder Rights Protection: Kaskela Law encourages current DexCom shareholders who have owned shares since at least April 28, 2023, to contact their attorneys to protect their rights in potential legal actions and ensure accountability from the company's executives.
Continue Reading